SCHEMBL29861748

SCHEMBL29861748

Cn1c(=O)c(Br)cc2c(O)ncnc21

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 7/20 0.33
CYP3A4 P08684 5/20 0.33
TSHR P16473 4/20 0.33
CLK4 Q9HAZ1 3/20 0.33
HSD17B10 Q99714 4/20 0.33
FEN1 P39748 1/20 0.33
ESR1 P03372 1/20 0.32
ESRRA P11474 1/20 0.32
ESR2 Q92731 1/20 0.32
ALDH1A1 P00352 3/20 0.32
MAPT P10636 1/20 0.32
ADORA2A P29274 1/20 0.32
ADORA2B P29275 1/20 0.32
ADORA1 P30542 1/20 0.32
PIK3CA P42336 3/20 0.32
USP2 O75604 3/20 0.32
PIK3CD O00329 1/20 0.32
ABL1 P00519 1/20 0.32
EGFR P00533 1/20 0.32
HCK P08631 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23326640 1.00 CYP1A2 (0.33) CYP1A2CYP3A4TSHRCLK4HSD17B10
SCHEMBL23326744 0.81 HSD17B10 (0.33) CYP1A2CYP3A4TSHRCLK4HSD17B10
SCHEMBL29861403 0.81 HSD17B10 (0.33) CYP1A2CYP3A4TSHRCLK4HSD17B10
SCHEMBL25396743 0.78 ALDH1A1 (0.38) CYP1A2TSHRHSD17B10ALDH1A1MAPT
SCHEMBL23326861 0.77 PIK3CA (0.36) HSD17B10ESR1ESRRAESR2ALDH1A1
SCHEMBL29861520 0.77 PIK3CA (0.36) HSD17B10ESR1ESRRAESR2ALDH1A1
SCHEMBL23345379 0.73 SOS1 (0.38) SOS1
Hydrochloric Acid SCHEMBL29910321 0.72 SOS1 (0.38) SOS1
Hydrochloric Acid SCHEMBL23326864 0.72 SOS1 (0.38) SOS1
SCHEMBL29918606 0.70 ESR2 (0.32) ESR2SOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116669738-A Pyrimidopyridone derivative as SOS1 inhibitor, and preparation method and application thereof 苏州阿尔脉生物科技有限公司 2023-08-29 CN disclosed
CN-116425742-A Bicyclic heteroaryl compounds and uses thereof 锐新医药公司 2023-07-14 CN disclosed
US-20220324862-A1 PYRIDOPYRIMIDINONE COMPOUNDS ACERAND THERAPEUTICS (USA) LIMITED 2022-10-13 US disclosed
WO-2022212531-A1 PYRIDOPYRIMIDINONE COMPOUNDS ACERAND THERAPEUTICS (USA) LIMITED (US) 2022-10-06 WO disclosed
CN-114901662-A Bicyclic heteroaryl compounds and uses thereof 锐新医药公司 2022-08-12 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220324862-A1 PYRIDOPYRIMIDINONE COMPOUNDS RSU1, SOST, CCNA1 CYP1A2 1271/4885CYP3A4 1147/4885TSHR 1615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.